SCHEMBL288640

SCHEMBL288640

OC1C2COCC1CN(Cc1ccccc1)C2

nearest known ligand 0.75

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.69
GBA1 P04062 1/20 0.54
DRD2 P14416 4/20 0.54
DRD3 P35462 4/20 0.54
ALDH1A1 P00352 1/20 0.49
GRIN2B Q13224 2/20 0.48
S1PR1 P21453 1/20 0.47
S1PR5 Q9H228 1/20 0.47
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22784440 1.00 FUCA1 (0.69) FUCA1GBA1DRD2DRD3ALDH1A1
SCHEMBL22784542 1.00 FUCA1 (0.69) FUCA1GBA1DRD2DRD3ALDH1A1
SCHEMBL15996691 1.00 FUCA1 (0.69) FUCA1GBA1DRD2DRD3ALDH1A1
SCHEMBL758420 1.00 FUCA1 (0.69) FUCA1GBA1DRD2DRD3ALDH1A1
SCHEMBL18517577 0.91 FUCA1 (0.65) FUCA1GBA1DRD2DRD3GRIN2B
SCHEMBL742892 0.91 FUCA1 (0.65) FUCA1GBA1DRD2DRD3GRIN2B
SCHEMBL23939426 0.89 FUCA1 (0.68) FUCA1GBA1DRD2DRD3ALDH1A1
SCHEMBL21561563 0.89 FUCA1 (0.68) FUCA1GBA1DRD2DRD3ALDH1A1
Hydrochloric Acid SCHEMBL11771300 0.89 FUCA1 (0.62) FUCA1GBA1DRD2DRD3GRIN2B
SCHEMBL1707693 0.86 FUCA1 (0.68) FUCA1GBA1DRD2DRD3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3983401-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2022-04-20 EP disclosed
US-10865194-B2 Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2020-12-15 US disclosed
US-20190135778-A1 THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2019-05-09 US disclosed
EP-1932844-B1 CROSS-LINKED CYCLIC AMINE COMPOUNDS AND AGENTS FOR PEST CONTROL NIPPON SODA CO (JP) 2015-09-02 EP disclosed
US-8912206-B2 Pyrimidine ether derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2014-12-16 US disclosed
US-8907095-B2 Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 MERCK SHARP & DOHME CORP. (US) 2014-12-09 US disclosed
US-8822480-B2 Bicyclic heterocycle derivatives and use thereof as GPR119 modulators MERCK SHARP & DOHME CORP. (US) 2014-09-02 US disclosed
US-8815876-B2 Bicyclic heterocycle derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2014-08-26 US disclosed
US-8697867-B2 Cross-linked cyclic amine compounds and agents for pest control NIPPON SODA CO., LTD. (JP) 2014-04-15 US disclosed
US-20130331569-A1 CROSS-LINKED CYCLIC AMINE COMPOUNDS AND AGENTS FOR PEST CONTROL NIPPON SODA CO., LTD. (JP) 2013-12-12 US disclosed
WO-2011061679-A1 IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS PFIZER INC. (US) 2011-05-26 WO disclosed
WO-2011036576-A1 GPR 119 MODULATORS PFIZER INC. (US) 2011-03-31 WO disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
WO-2010106457-A2 3-OXA-7-AZABICYCLO[3.3.1]NONANES PFIZER INC. (US) 2010-09-23 WO disclosed
US-20090318694-A1 Cross-Linked Amine Compounds and Agents for Pest Control NIPPON SODA CO., LTD. (JP) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135778-A1 THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS NAAA, FAAH, FAAH2 FUCA1 458/4885GBA1 63/4885DRD2 2741/4885
US-10865194-B2 Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions NAAA, FAAH2, FAAH FUCA1 397/4885GBA1 70/4885DRD2 1467/4885
US-20100285145-A1 GPR 119 MODULATORS GPR119, GPR65, GPR39 FUCA1 1888/4885GBA1 952/4885DRD2 1425/4885
US-20130331569-A1 CROSS-LINKED CYCLIC AMINE COMPOUNDS AND AGENTS FOR PEST CONTROL CYCS, NPY1R, CYBB FUCA1 4246/4885GBA1 2552/4885DRD2 731/4885
US-20090318694-A1 Cross-Linked Amine Compounds and Agents for Pest Control CYCS, NPY1R, CYBB FUCA1 4191/4885GBA1 2245/4885DRD2 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.